The aim of the study was to identify and describe new signaling pathways, leading to an activation of the transcription factor myocyte enhancer factor 2 (MEF2), a central regulator of adverse cardiac remodeling, and thereby potentially contributing to the pathogenesis of heart failure. Here, MEF2A is linked to heart failure.